Implication of the New Low-Density Lipoprotein Goals in Dyslipidemia Management of Patients With Acute Coronary Syndrome

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001, Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 LaRosa, 2005, Intensive lipid lowering with atorvastatin in patients with stable coronary disease, N Engl J Med, 352, 1425, 10.1056/NEJMoa050461 Cannon, 2004, Intensive and moderate lipid lowering with statins after acute coronary syndromes [published correction appears in N Engl J Med. 2006; 354:778], N Engl J Med, 350, 1495, 10.1056/NEJMoa040583 Heart Protection Study Collaborative Group, 2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3 Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines, J Am Coll Cardiol, 44, 720, 10.1016/j.jacc.2004.07.001 Jackson, 1987, Changes in serum lipid concentrations during first 24 hours after myocardial infarction, Br Med J (Clin Res Ed), 294, 1588, 10.1136/bmj.294.6587.1588 Rosenson, 1993, Myocardial injury: the acute phase response and lipoprotein metabolism, J Am Coll Cardiol, 22, 933, 10.1016/0735-1097(93)90213-K Tatum, 1997, Comprehensive strategy for the evaluation and triage of the chest pain patient, Ann Emerg Med, 29, 116, 10.1016/S0196-0644(97)70317-2 Alpert, 2000, Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction [published correction appears in J Am Coll Cardiol. 2001; 37:973], J Am Coll Cardiol, 36, 959 Roberts, 1997, The rule of 5 and the rule of 7 in lipid-lowering by statin drugs [editorial], Am J Cardiol, 80, 106, 10.1016/S0002-9149(97)00298-1 Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383 Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, 1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902 Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401 Antman, 2004, J Am Coll Cardiol, 44, 671, 10.1016/j.jacc.2004.07.002 Brewer, 2003, Benefit-risk assessment of rosuvastatin 10 to 40 milligrams, Am J Cardiol, 92, 23K, 10.1016/S0002-9149(03)00779-3 Jones, 2003, Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial), Am J Cardiol, 92, 152, 10.1016/S0002-9149(03)00530-7 Ballantyne, 2004, Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia, Am J Cardiol, 93, 1487, 10.1016/j.amjcard.2004.02.060 Ballantyne, 2003, Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial, Circulation, 107, 2409, 10.1161/01.CIR.0000068312.21969.C8 Nam, 2006, Search for an optimal atherogenic lipid profile: from the Framingham Study, Am J Cardiol, 97, 372, 10.1016/j.amjcard.2005.08.055